CD82 was first reported as a potential marker for breast cancer metastasis by Yang et al. [39], who demonstrated that the metastatic propensity of a variety of breast cancer cell lines was inversely correlated with CD82/KAIl mRNA expression. Here, CD82 is linked to breast carcinoma.